UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 25, 2011
 

HELIX BIOMEDIX, INC.
(Exact name of registrant as specified in its charter)

 
DELAWARE
033-20897-D
91-2099117
(State or other jurisdiction
of incorporation or organization)
(Commission
File Number)
(IRS Employer
Identification No.)
 
22118 20th Avenue S.E., Suite 204
Bothell, Washington 98021
(425) 402-8400
(Address and telephone number of registrant’s principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
 
Item 5.07  Submission of Matters to a Vote of Security Holders.

The 2011 Annual Meeting of the Stockholders of Helix BioMedix, Inc. (the “Company”) was held on May 25, 2011, at which the following matters were approved as follows:

1.  
The election of the following Class II director to serve until the 2014 Annual Meeting of Stockholders or until such director’s successor is elected and qualified:

Nominee
  For
  
Withheld  
Broker Non-Votes
Jeffrey A. Miller
 
33,683,270
 
203,570
 
6,567,113

2.  
The approval of the Company’s 2011 Stock Option Plan:

For
 
Against
 
Abstain
 
Broker Non-Votes
33,082,974
 
706,002
 
97,864
  6,567,113

3.  
The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011:
 
For
 
Against
 
Abstain
 
Broker Non-Votes
39,968,645
 
59,252
  426,056
  
0
 
 These are the final voting results.
 
 
 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
HELIX BIOMEDIX, INC.
       
Dated: May 27, 2011
 
By:
/s/ R. Stephen Beatty
       
R. Stephen Beatty
       
President and Chief Executive Officer